Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines

Melanoma Research

Volumn 23, Issue 5, 2013, Pages 360-365

  Johansson, Carolina Hertzman ^a   Azimi, Alireza ^a   Stolt, Marianne Frostvik ^a   Shojaee, Seyedmehdi ^a   Wiberg, Henning ^a   Grafström, Eva ^a   Hansson, Johan ^a   Brage, Suzanne Egyházi ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy resistance; Dacarbazine; Gp100 PMEL; GPR143; Melanogenesis; Melanoma; Melanosomes; MITF; Temozolomide

Indexed keywords

CARBOPLATIN; CISPLATIN; DACARBAZINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 143; MELANOCYTE PROTEIN PMEL 17; MELANOSOME RELATED PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MLANA PROTEIN; PACLITAXEL; RAB27A PROTEIN; RECOMBINANT INTERLEUKIN 2; SMALL INTERFERING RNA; TEMOZOLOMIDE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; TYRP1 PROTEIN; UNCLASSIFIED DRUG; VINDESINE; ANTINEOPLASTIC AGENT; EYE PROTEIN; GPR143 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITF PROTEIN, HUMAN; PMEL PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOGENESIS; MELANOMA; MELANOMA CELL; MELANOSOME; METASTATIC MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN METASTASIS; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR VOLUME; COMPARATIVE STUDY; DOSE RESPONSE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; IC50; METABOLISM; MIDDLE AGED; PATHOLOGY; RNA INTERFERENCE; SKIN NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; EYE PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GP100 MELANOMA ANTIGEN; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MELANOMA; MELANOSOMES; MEMBRANE GLYCOPROTEINS; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MIDDLE AGED; RNA INTERFERENCE; SKIN NEOPLASMS; TRANSCRIPTION, GENETIC; TRANSFECTION; TREATMENT OUTCOME;

EID: 84888008625     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328362f9cd     Document Type: Article

References (19)

1. Wright PK. Targeting vesicle trafficking: an important approach to cancer chemotherapy. Recent Pat Anticancer Drug Discov 2008; 3:137-147.
2. Huang ZM, Chinen M, Chang PJ, Xie T, Zhong L, Demetriou S, et al. Targeting protein-trafficking pathways alters melanoma treatment sensitivity. Proc Natl Acad Sci USA 2012; 109:553-558.
3. Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, et al. Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci USA 2006; 103:9903-9907.
4. Xie T, Nguyen T, Hupe M, Wei ML. Multidrug resistance decreases with mutations of melanosomal regulatory genes. Cancer Res 2009; 69:992-999.
5. Chen KG, Leapman RD, Zhang G, Lai B, Valencia JC, Cardarelli CO, et al. Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst 2009; 101:1259-1271.
6. Raposo G, Marks MS. Melanosomes-dark organelles enlighten endosomal membrane transport. Nat Rev Mol Cell Biol 2007; 8:786-797.
7. Eskandarpour M, Huang F, Reeves KA, Clark E, Hansson J. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer 2009; 124:16-26.
8. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
10. Giordano F, Bonetti C, Surace EM, Marigo V, Raposo G. The ocular albinism type 1 (OA1) G-protein-coupled receptor functions with MART-1 at early stages of melanogenesis to control melanosome identity and composition. Hum Mol Genet 2009; 18:4530-4545.
11. Palmisano I, Bagnato P, Palmigiano A, Innamorati G, Rotondo G, Altimare D, et al. The ocular albinism type 1 protein, an intracellular G protein-coupled receptor, regulates melanosome transport in pigment cells. Hum Mol Genet 2008; 17:3487-3501.
12. Haq R, Fisher DE. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 2011; 29:3474-3482.
13. Bell RE, Levy C. The three M's: melanoma, microphthalmia-associated transcription factor and microRNA. Pigment Cell Melanoma Res 2011; 24:1088-1106.
14. Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, et al. Novel MITF targets identified using a two-step DNA microarray strategy. Pigment Cell Melanoma Res 2008; 21:665-676.
15. Strub T, Giuliano S, Ye T, Bonet C, Keime C, Kobi D, et al. Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma. Oncogene 2011; 30:2319-2332.
16. Ugurel S, Houben R, Schrama D, Voigt H, Zapatka M, Schadendorf D, et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res 2007; 13:6344-6350.
17. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436:117-122.
18. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009; 4:e4563.
19. Craig EA, Spiegelman VS. Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents. Pigment Cell Melanoma Res 2011; 25:83-87.